Total Payments
$36,321
2024 Payments
$20,066
Companies
13
Transactions
93
Medicare Patients
1,572
Medicare Billing
$176,732
Payment Breakdown by Category
Other$27,180 (74.8%)
Food & Beverage$4,536 (12.5%)
Consulting$3,500 (9.6%)
Travel$1,073 (3.0%)
Education$32.27 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $17,980 | 6 | 49.5% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $7,200 | 4 | 19.8% |
| Food and Beverage | $4,536 | 76 | 12.5% |
| Consulting Fee | $3,500 | 1 | 9.6% |
| Honoraria | $2,000 | 3 | 5.5% |
| Travel and Lodging | $1,073 | 2 | 3.0% |
| Education | $32.27 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Madrigal Pharmaceuticals | $19,958 | 16 | $0 (2024) |
| INTERCEPT PHARMACEUTICALS, INC. | $9,749 | 12 | $0 (2023) |
| ABBVIE INC. | $5,190 | 25 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $523.35 | 20 | $0 (2023) |
| W. L. Gore & Associates, Inc. | $179.05 | 1 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $132.03 | 1 | $0 (2023) |
| Novo Nordisk Inc | $126.75 | 4 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $118.26 | 1 | $0 (2018) |
| Gilead Sciences, Inc. | $107.83 | 8 | $0 (2024) |
| Covidien LP | $94.72 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $20,066 | 21 | Madrigal Pharmaceuticals ($19,958) |
| 2023 | $207.02 | 5 | AstraZeneca Pharmaceuticals LP ($132.03) |
| 2022 | $369.82 | 11 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($207.81) |
| 2021 | $895.09 | 6 | Intercept Pharmaceuticals, Inc. ($750.00) |
| 2020 | $5,667 | 11 | Intercept Pharmaceuticals, Inc. ($5,481) |
| 2019 | $7,225 | 11 | AbbVie, Inc. ($3,737) |
| 2018 | $1,155 | 13 | AbbVie, Inc. ($828.58) |
| 2017 | $736.10 | 15 | AbbVie, Inc. ($568.68) |
All Payment Transactions
93 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $15.35 | General |
| Category: Cardio-renal | ||||||
| 12/04/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/04/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $132.11 | General |
| Category: LIVER DISEASE | ||||||
| 11/21/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $112.64 | General |
| Category: LIVER DISEASE | ||||||
| 10/30/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,763.00 | General |
| Category: LIVER DISEASE | ||||||
| 10/23/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,763.00 | General |
| Category: LIVER DISEASE | ||||||
| 10/16/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 10/16/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $945.00 | General |
| Category: LIVER DISEASE | ||||||
| 10/16/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $98.97 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,935.00 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $186.86 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | Cash or cash equivalent | $128.24 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $94.62 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $80.91 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $77.39 | General |
| Category: LIVER DISEASE | ||||||
| 09/17/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.02 | General |
| 09/11/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 09/11/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $121.48 | General |
| Category: LIVER DISEASE | ||||||
| 07/25/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $15.81 | General |
| 05/30/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $15.88 | General |
| Category: Cardio-renal | ||||||
| 03/29/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $38.78 | General |
| Category: VIROLOGY | ||||||
| 12/27/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $15.32 | General |
| Category: Gastroenterology | ||||||
| 09/20/2023 | INTERCEPT PHARMACEUTICALS, INC. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $18.23 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 05/11/2023 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $16.63 | General |
| Category: VIROLOGY | ||||||
| 04/13/2023 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $132.03 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 376 | 500 | $178,908 | $38,714 |
| 2022 | 15 | 353 | 482 | $173,204 | $38,086 |
| 2021 | 13 | 385 | 518 | $200,114 | $46,223 |
| 2020 | 15 | 458 | 652 | $262,594 | $53,709 |
Total Patients
1,572
Total Services
2,152
Medicare Billing
$176,732
Procedure Codes
58
All Medicare Procedures & Services
58 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 84 | 114 | $38,190 | $12,100 | 31.7% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 56 | 82 | $20,500 | $6,291 | 30.7% |
| 43244 | Tying of dilated veins of stomach and/or esophagus using a flexible endoscope | Facility | 2023 | 25 | 29 | $43,645 | $5,615 | 12.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 40 | 43 | $20,844 | $4,739 | 22.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 29 | 53 | $11,501 | $3,586 | 31.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 16 | 19 | $4,522 | $1,330 | 29.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 24 | 26 | $4,862 | $1,265 | 26.0% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 24 | 25 | $22,500 | $1,236 | 5.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2023 | 16 | 16 | $6,160 | $1,080 | 17.5% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 12 | 12 | $2,592 | $826.44 | 31.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 17 | 47 | $940.00 | $387.87 | 41.3% |
| 91200 | Measurement of liver stiffness | Facility | 2023 | 33 | 34 | $2,652 | $258.85 | 9.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 64 | 84 | $28,140 | $9,134 | 32.5% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 71 | 94 | $23,500 | $6,950 | 29.6% |
| 43244 | Tying of dilated veins of stomach and/or esophagus using a flexible endoscope | Facility | 2022 | 19 | 24 | $36,120 | $4,648 | 12.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 24 | 51 | $11,091 | $2,939 | 26.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 13 | 13 | $8,079 | $2,249 | 27.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 17 | 25 | $7,775 | $2,211 | 28.4% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 19 | 20 | $9,618 | $2,197 | 22.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 12 | 12 | $5,208 | $1,448 | 27.8% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 22 | 25 | $22,500 | $1,413 | 6.3% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 15 | 16 | $5,496 | $1,404 | 25.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 16 | 17 | $4,046 | $1,266 | 31.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 12 | 12 | $4,872 | $804.76 | 16.5% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2022 | 13 | 14 | $2,450 | $674.25 | 27.5% |
About Dr. Christopher Moore, MD
Dr. Christopher Moore, MD is a Hepatology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/16/2007. The National Provider Identifier (NPI) number assigned to this provider is 1740496512.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Moore, MD has received a total of $36,321 in payments from pharmaceutical and medical device companies, with $20,066 received in 2024. These payments were reported across 93 transactions from 13 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($17,980).
As a Medicare-enrolled provider, Moore has provided services to 1,572 Medicare beneficiaries, totaling 2,152 services with total Medicare billing of $176,732. Data is available for 4 years (2020–2023), covering 58 distinct procedure/service records.
Ad
Practice Information
- Specialty Hepatology
- Location Chicago, IL
- Active Since 05/16/2007
- Last Updated 08/27/2014
- Taxonomy Code 207RI0008X
- Entity Type Individual
- NPI Number 1740496512
Products in Payments
- REZDIFFRA (Drug) $19,846
- OCALIVA (Drug) $9,749
- Mavyret (Drug) $4,515
- XIFAXAN (Drug) $399.56
- Viekira (Drug) $357.49
- EXCLUDER AAA Endoprosthesis (Device) $179.05
- LYNPARZA (Drug) $132.03
- PLENVU (Drug) $123.79
- RESMETIROM (Drug) $112.64
- Beacon (Device) $94.72
- Kerecis Omega3 Wound (Device) $94.48
- MAVYRET (Drug) $55.41
- Ozempic (Drug) $32.27
- Kerendia (Drug) $31.23
- RESTASIS (Drug) $16.15
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hepatology Doctors in Chicago
Daniel Ganger, Md, MD
Hepatology — Payments: $121,361
Hepatology $121,361
Dr. Veronica Loy, Do, DO
Hepatology — Payments: $51,462
Hepatology $51,462
Richard Green, Md, MD
Hepatology — Payments: $13,429
Hepatology $13,429
Andres Duarte, Md, MD
Hepatology — Payments: $10,252
Hepatology $10,252
Dr. Estella Alonso, M.d, M.D
Hepatology — Payments: $2,392
Hepatology $2,392
Dr. Nabeel Wahid, Md, MD
Hepatology — Payments: $882.30
Hepatology $882.30